BioCentury
ARTICLE | Emerging Company Profile

Indalo: Integral to fibrosis

How Indalo antagonizes multiple integrins to inhibit pro-fibrotic processes

February 14, 2019 9:57 PM UTC

Indalo Therapeutics Inc. is targeting the root causes in fibrosis by antagonizing multiple integrins simultaneously to disrupt disease-associated processes, not just those driven by a single integrin or TGFβ signaling.

Indalo President and CEO Robert Jacks said other fibrosis companies focus on the process by which integrins, particularly integrin αvβ6, activate transforming growth factor β (TGFβ), but do not address other integrin-mediated fibrotic processes, such as the promotion of fibroblast migration and survival by stiff extracellular matrix (ECM). “We at Indalo are focused on multiple processes in the fibrotic cascade that are all modulated by integrins.” ...

BCIQ Company Profiles

Indalo Therapeutics Inc.